1. Monash Health
  2. Monash Health research
  3. Articles
Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/31883
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGearing A.J.H.en
dc.date.accessioned2021-05-14T10:47:35Zen
dc.date.available2021-05-14T10:47:35Zen
dc.date.copyright2007en
dc.date.created20070919en
dc.date.issued2012-10-17en
dc.identifier.citationImmunology and Cell Biology. 85 (6) (pp 490-494), 2007. Date of Publication: August 2007.en
dc.identifier.issn0818-9641en
dc.identifier.urihttps://repository.monashhealth.org/monashhealthjspui/handle/1/31883en
dc.description.abstractToll-like receptors (TLRs) play a fundamental role in recognizing infectious and noxious agents as well as products of tissue damage. They are capable of initiating both protective and damaging inflammatory and immune responses. Several biotechnology and pharmaceutical companies have programmes to develop new drugs that are either: agonists of TLRs to enhance immune responses against tumours and infectious agents, or to correct allergic responses; or antagonists designed to reduce inflammation due to infection or autoimmune disease. This article reviews the commercial approaches being undertaken to develop new TLR drugs. © 2007 Australasian Society for Immunology Inc. All rights reserved.en
dc.languageEnglishen
dc.languageenen
dc.publisherNature Publishing Group (Houndmills, Basingstoke, Hampshire RG21 6XS, United Kingdom)en
dc.titleTargeting toll-like receptors for drug development: A summary of commercial approaches.en
dc.typeReviewen
dc.type.studyortrialReview article (e.g. literature review, narrative review)-
dc.identifier.doihttp://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1038/sj.icb.7100102en
dc.publisher.placeUnited Kingdomen
dc.identifier.pubmedid17667933 [http://www.ncbi.nlm.nih.gov/pubmed/?term=17667933]en
dc.identifier.source47367512en
dc.identifier.institution(Gearing) Biocomm Squared, Monash Institute of Medical Research, Monash University, Clayton, Vic., Australia (Gearing) Biocomm Squared, Monash Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australiaen
dc.description.addressA.J.H. Gearing, Biocomm Squared, Monash Institute of Medical Research, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia. E-mail: gearing@biocommsquared.com.auen
dc.description.publicationstatusEmbaseen
dc.rights.statementCopyright 2012 Elsevier B.V., All rights reserved.en
dc.subect.keywordsCommercial approaches Drug targets Toll-like receptorsen
dc.identifier.authoremailGearing A.J.H.; gearing@biocommsquared.com.auen
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.openairetypeReview-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
Appears in Collections:Articles
Show simple item record

Page view(s)

2
checked on Sep 14, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.